{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:26:41Z","timestamp":1791228401551,"version":"4.1.0"},"reference-count":67,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,12,27]],"date-time":"2014-12-27T00:00:00Z","timestamp":1419638400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Spanish Foundation of Rheumatology"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To analyze lipid changes in patients with rheumatoid arthritis (RA) and patients with spondyloarthritis (SpA) treated with biologic agents or tofacitinib in randomized clinical trials (RCTs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature search was performed, using the Medline, Embase, Cochrane Library, and Web of Knowledge databases. Meta\u2010analyses were performed using random\u2010effects models to assess changes in the percentage of patients with abnormal lipid values or in the mean percentage of increase in the cholesterol and triglycerides levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Twenty\u2010five of 4,527 identified articles met the inclusion criteria. Compared with RA patients treated with placebo, those treated with tocilizumab were more likely to have hypercholesterolemia (odds ratio [OR] 4.64; 95% confidence interval [95% CI] 2.71, 7.95 [\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001]), increased levels of high\u2010density lipoprotein (HDL) cholesterol (OR 2.25; 95% CI 1.14, 4.44 [\n                      <jats:italic>P<\/jats:italic>\n                      = 0.020]), and increased levels of low\u2010density lipoprotein (LDL) cholesterol (OR 4.80; 95% CI 3.27, 7.05 [\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001]); this was not observed in patients treated with tumor necrosis factor (TNF) antagonists (OR 1.54; 95% CI 0.90, 2.66 [\n                      <jats:italic>P<\/jats:italic>\n                      = 0.119]) or tofacitinib (OR 3.4; 95% CI 0.62, 18.55 [\n                      <jats:italic>P<\/jats:italic>\n                      = 0.158]). Among patients receiving tofacitinib 5 mg twice daily, the mean percentage of increases in the HDL cholesterol level (weighted mean difference [WMD] 13.00 mg\/dl; 95% CI 12.08, 13.93 [\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001]) and the LDL cholesterol level (WMD 11.20 mg\/dl; 95% CI 10.08, 12.32 [\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001]) were higher than those in the comparator groups. Among patients treated with tofacitinib 10 mg twice daily, the mean percentage of increases in the HDL cholesterol level (WMD 15.21 mg\/dl; 95% CI 13.28, 17.14 [\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001]) and the LDL cholesterol level (WMD 15.42 mg\/dl; 95% CI 11.77, 19.06 [\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.001]) were also higher than those in the comparator groups. No data were available for RA treated with other biologic agents or for SpA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with RA treated with tocilizumab or tofacitinib but not with TNF antagonists, moderate changes in lipids are observed. Whether these changes pertain to the control of inflammation or to the mechanism of action of the biologic agents or tofacitinib remains undetermined.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.38894","type":"journal-article","created":{"date-parts":[[2014,10,9]],"date-time":"2014-10-09T11:17:54Z","timestamp":1412853474000},"page":"117-127","source":"Crossref","is-referenced-by-count":146,"title":["Lipid Profile Changes in Patients With Chronic Inflammatory Arthritis Treated With Biologic Agents and Tofacitinib in Randomized Clinical Trials: A Systematic Review and Meta\u2010Analysis"],"prefix":"10.1002","volume":"67","author":[{"given":"Alejandro","family":"Souto","sequence":"first","affiliation":[{"name":"Complejo Hospitalario Universitario de Santiago de Compostela Santiago Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Salgado","sequence":"additional","affiliation":[{"name":"Complejo Hospitalario Universitario de Santiago de Compostela Santiago Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ram\u00f3n","family":"Maneiro","sequence":"additional","affiliation":[{"name":"Complejo Hospitalario Universitario de Santiago de Compostela Santiago Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Mera","sequence":"additional","affiliation":[{"name":"Complejo Hospitalario Universitario de Santiago de Compostela Santiago Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreto","family":"Carmona","sequence":"additional","affiliation":[{"name":"Complejo Hospitalario Universitario de Santiago de Compostela, Santiago, Spain, and Instituto de Salud Musculoesquel\u00e9tica Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J.","family":"G\u00f3mez\u2010Reino","sequence":"additional","affiliation":[{"name":"Complejo Hospitalario Universitario de Santiago de Compostela, Santiago, Spain, and Universidad de Santiago Santiago Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,12,27]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10089"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2012.06.016"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-012-0260-8"},{"key":"e_1_2_7_5_1","first-page":"36","article-title":"Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis","volume":"30","author":"Wolfe F","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24092"},{"key":"e_1_2_7_7_1","first-page":"32","article-title":"Mortality and causes of death in psoriatic arthritis","volume":"89","author":"Arumugam R","year":"2012","journal-title":"J Rheumatol"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21204"},{"key":"e_1_2_7_9_1","first-page":"1219","article-title":"High\u2010grade C\u2010reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis","volume":"32","author":"Gonzalez\u2010Gay MA","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11078"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200112)44:12<2737::AID-ART460>3.0.CO;2-#"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000099844.31524.05"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000028581.07992.56"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.56.6.374"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.06.054"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.023119"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/785946"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.086728"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22809"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23940"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112072"},{"issue":"3","key":"e_1_2_7_22_1","first-page":"388","article-title":"Assessment of arterial stiffness after 24 weeks of abatacept therapy in 17 patients with rheumatoid arthritis","author":"Mathieu S","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_7_23_1","first-page":"S157","article-title":"Assessment of cardiovascular markers after 24 weeks of abatacept or rituximab therapy in patients with rheumatoid arthritis","volume":"62","author":"Mathieu S","year":"2010","journal-title":"Arthritis Rheum"},{"key":"e_1_2_7_24_1","first-page":"446","article-title":"Increased lipid levels but unchanged atherogenic index in rheumatoid arthritis patients treated with biologic disease modifying antirheumatic drugs: published experience","volume":"27","author":"Schimmel EK","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201228"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00136"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00134-4"},{"key":"e_1_2_7_29_1","unstructured":"OCEBM Levels of Evidence Working Group. The Oxford 2011 levels of evidence. Oxford: Oxford Centre for Evidence\u2010Based Medicine. URL:http:\/\/cebm.net\/index.aspx?o=5653."},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1186"},{"key":"e_1_2_7_34_1","unstructured":"Department of Health and Human Services: Food and Drug Administration. BLA no. 125289\/S\u2010000 Simponi (golimumab) for the signs and symptoms of RA PsA and AS.2009. URL:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/125289_MedR_P5.pdf."},{"key":"e_1_2_7_35_1","unstructured":"Department of Health and Human Services: Food and Drug Administration. Labeling Revision of Adalimumab. Reference ID: 3307696.2013. URL:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/125057s310lbl.pdf."},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61424-X"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0929-6646(09)60071-1"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092932"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33383"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109071"},{"key":"e_1_2_7_41_1","first-page":"486","article-title":"Impact of adalimumab therapy on laboratory parameters of interest in patients with early or long\u2010standing rheumatoid arthritis","volume":"64","author":"Furst D","year":"2012","journal-title":"Arthritis Rheum"},{"key":"e_1_2_7_42_1","first-page":"2563","article-title":"Adalimumab, a fully human anti tumor necrosis factor\u2010\u03b1 monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)","volume":"30","author":"Furst DE","year":"2003","journal-title":"J Rheumatol"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.105197"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1479-8077.2007.00248.x"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202089"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33419"},{"issue":"3","key":"e_1_2_7_47_1","first-page":"73","article-title":"Measure: A translational, randomized, placebo (PBO)\u2010controlled study to evaluate the effects of tocilizumab (TCZ) on parameters of lipids and inflammation","author":"McInnes IB","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-008-0125-1"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60506-7"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120541"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20494"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.009563"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.37816"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.148700"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.122374"},{"issue":"3","key":"e_1_2_7_56_1","first-page":"78","article-title":"Lipid profile improves with the onset of rheumatoid arthritis","author":"Myasoedova E","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"e_1_2_7_57_1","first-page":"1701","article-title":"Lipid profiles in untreated patients with rheumatoid arthritis","volume":"26","author":"Park YB","year":"1999","journal-title":"J Rheumatol"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22166"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201148"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/765624"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-1303-y"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-010-0279-5"},{"key":"e_1_2_7_63_1","first-page":"S531","article-title":"Lipid and inflammatory biomarkers in patients receiving tocilizumab for rheumatoid arthritis: analysis of five phase 3 clinical trials [abstract]","volume":"58","author":"Genovese MC","year":"2008","journal-title":"Arthritis Rheum 2008"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-1716.2007.01779.x"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-128-2-199801150-00009"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003668"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2013.03.019"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-012-0270-6"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.38894","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.38894","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T16:38:02Z","timestamp":1759941482000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.38894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,27]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1002\/art.38894"],"URL":"https:\/\/doi.org\/10.1002\/art.38894","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,27]]}}}